NOT that I remotely suggesting it statistically significant at only 15 patients (or being critical of MSB before the usual recriminations start) but MSB's recent GvHD trial reported:
"Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults".
CYP reported "Patients treated with CYP-001 had a two-year overall survival rate of 60% (9/15 patients)" by comparison in its small phase 1 trial.
- Forums
- ASX - By Stock
- CYP
- Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT
Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-2
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $52.99M |
Open | High | Low | Value | Volume |
28.0¢ | 29.5¢ | 27.5¢ | $29.94K | 106.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 27.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 10159 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.275 |
1 | 1492 | 0.270 |
1 | 77000 | 0.260 |
2 | 9125 | 0.245 |
3 | 125942 | 0.240 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 10159 | 1 |
0.310 | 16591 | 3 |
0.325 | 15000 | 1 |
0.340 | 100000 | 1 |
0.345 | 6124 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online